This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Oct 10;28(29):e563-4; author reply e565-6.

doi: 10.1200/JCO.2010.30.1010. Epub 2010 Aug 2.

BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors

Jurgen Veeck, Santiago Ropero, Fernando Setien, Eva Gonzalez-Suarez, Ana Osorio, Javier Benitez, James G Herman, Manel Esteller

PMID: 20679605
DOI: 10.1200/JCO.2010.30.1010

Free article

Comment

BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors

Jurgen Veeck et al. J Clin Oncol. 2010.

Free article

. 2010 Oct 10;28(29):e563-4; author reply e565-6.

doi: 10.1200/JCO.2010.30.1010. Epub 2010 Aug 2.

Authors

Jurgen Veeck, Santiago Ropero, Fernando Setien, Eva Gonzalez-Suarez, Ana Osorio, Javier Benitez, James G Herman, Manel Esteller

PMID: 20679605
DOI: 10.1200/JCO.2010.30.1010

No abstract available

PubMed Disclaimer

Comment on

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB. Fong PC, et al. J Clin Oncol. 2010 May 20;28(15):2512-9. doi: 10.1200/JCO.2009.26.9589. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406929 Clinical Trial.

Similar articles

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Gelmon KA, et al. Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19. Lancet Oncol. 2011. PMID: 21862407 Clinical Trial.
PARP inhibitors: targeting the right patients.
Azvolinsky A. Azvolinsky A. J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10. J Natl Cancer Inst. 2012. PMID: 23231976 No abstract available.
Olaparib (Lynparza) for advanced ovarian cancer.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 Feb 29;58(1489):e32-3. Med Lett Drugs Ther. 2016. PMID: 26938702 Review. No abstract available.
[Hereditary ovarian carcinomas: clinico-biological features and treatment].
Floquet A, Stoeckle E, Croce S, Longy M, Mc Grogan G, Barouk E, Bubien V, Garbay D, Joly E, Guyon F. Floquet A, et al. Bull Cancer. 2014 Feb;101(2):167-74. doi: 10.1684/bdc.2014.1888. Bull Cancer. 2014. PMID: 24555961 Review. French.
BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM, Garber JE. Tung NM, et al. Br J Cancer. 2018 Jul;119(2):141-152. doi: 10.1038/s41416-018-0127-5. Epub 2018 Jun 5. Br J Cancer. 2018. PMID: 29867226 Free PMC article. Review.

See all similar articles

Cited by

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M. Stefansson OA, et al. Epigenetics. 2012 Nov;7(11):1225-9. doi: 10.4161/epi.22561. Epub 2012 Oct 15. Epigenetics. 2012. PMID: 23069641 Free PMC article.
The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women.
Prabhu JS, Wahi K, Korlimarla A, Correa M, Manjunath S, Raman N, Srinath BS, Sridhar TS. Prabhu JS, et al. Tumour Biol. 2012 Apr;33(2):315-23. doi: 10.1007/s13277-012-0343-1. Epub 2012 Feb 24. Tumour Biol. 2012. PMID: 22362381
Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays.
de Ruijter TC, de Hoon JP, Slaats J, de Vries B, Janssen MJ, van Wezel T, Aarts MJ, van Engeland M, Tjan-Heijnen VC, Van Neste L, Veeck J. de Ruijter TC, et al. Lab Invest. 2015 Jul;95(7):833-42. doi: 10.1038/labinvest.2015.53. Epub 2015 Apr 13. Lab Invest. 2015. PMID: 25867767
BRCAness: finding the Achilles heel in ovarian cancer.
Rigakos G, Razis E. Rigakos G, et al. Oncologist. 2012;17(7):956-62. doi: 10.1634/theoncologist.2012-0028. Epub 2012 Jun 6. Oncologist. 2012. PMID: 22673632 Free PMC article. Review.
Omics Technologies Improving Breast Cancer Research and Diagnostics.
Orsini A, Diquigiovanni C, Bonora E. Orsini A, et al. Int J Mol Sci. 2023 Aug 11;24(16):12690. doi: 10.3390/ijms241612690. Int J Mol Sci. 2023. PMID: 37628869 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal